OS Therapies Stock (NYSE:OSTX)

Financials Chart

Previous Close

$2.20

52W Range

$1.12 - $7.00

50D Avg

$1.94

200D Avg

$2.14

Market Cap

$73.55M

Avg Vol (3M)

$609.64K

Beta

-3.94

Div Yield

-

OSTX Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

4

IPO Date

Aug 01, 2024

Website

OSTX Performance

OSTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-6.81B	$-4.34M	$-4.45M
Net Income	$-8.88B	$-7.79M	$-6.25M
EBITDA	$-6.81B	$-4.34M	$-4.45M
Basic EPS	$-71.77	$-0.39	$-0.28
Diluted EPS	$-71.77	$-0.39	$-0.28

Fiscal year ends in Dec 24 | Currency in USD